Bat-borne emerging zoonotic viruses cause major outbreaks, such as the Ebola virus, Nipah virus, severe acute respiratory syndrome (SARS) coronavirus, and SARS-CoV-2. Pteropine orthoreovirus (PRV), which spillover event occurred from fruit bats to humans, causes respiratory syndrome in humans widely in South East Asia. Repurposing approved drugs against PRV is a critical tool to confront future PRV pandemics. We screened 2,943 compounds in an FDA-approved drug library and identified eight hit compounds that reduce viral cytopathic effects on cultured Vero cells. Real-time quantitative PCR analysis revealed that six of eight hit compounds significantly inhibited PRV replication. Among them, micafungin used clinically as an antifungal drug, displayed a prominent antiviral effect on PRV.

中文翻译：

---

FDA 批准的药物筛选确定米卡芬净是一种抗病毒剂，可对抗蝙蝠传播的新兴人畜共患 Pteropine 正呼肠孤病毒

蝙蝠传播的新出现的人畜共患病病毒会导致大规模爆发，例如埃博拉病毒、尼帕病毒、严重急性呼吸系统综合症 (SARS) 冠状病毒和 SARS-CoV-2。Pteropine Orthoreovirus (PRV) 从果蝠传播到人类，在东南亚广泛引起人类呼吸综合征。重新利用已批准的抗 PRV 药物是应对未来 PRV 大流行的关键工具。我们筛选了 FDA 批准的药物库中的 2,943 种化合物，并确定了 8 种降低病毒对培养的 Vero 细胞的细胞病变影响的热门化合物。实时定量 PCR 分析显示，八种命中化合物中有六种显着抑制了 PRV 复制。其中，临床上用作抗真菌药物的米卡芬净对PRV表现出显着的抗病毒作用。